Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries

20-HETE, a cytochrome P-450 4A (CYP4A1)-derived arachidonic acid metabolite, is a major eicosanoid formed in renal and extrarenal microcirculation. 20-HETE inhibits Ca(2+)-activated K(+) channels in vascular smooth muscle cells and thereby may modulate vascular reactivity. We transfected renal inter...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Renal physiology Vol. 284; no. 1; pp. F51 - F56
Main Authors Kaide, Jun-Ichi, Wang, Mong-Heng, Wang, Ji-Shi, Zhang, Fan, Gopal, V Raj, Falck, John R, Nasjletti, Alberto, Laniado-Schwartzman, Michal
Format Journal Article
LanguageEnglish
Published United States 01.01.2003
Subjects
Online AccessGet full text

Cover

Loading…
Abstract 20-HETE, a cytochrome P-450 4A (CYP4A1)-derived arachidonic acid metabolite, is a major eicosanoid formed in renal and extrarenal microcirculation. 20-HETE inhibits Ca(2+)-activated K(+) channels in vascular smooth muscle cells and thereby may modulate vascular reactivity. We transfected renal interlobar arteries with an expression plasmid containing the cDNA of CYP4A1, the low-K(m) arachidonic acid omega-hydroxylase, and examined the consequences of increasing 20-HETE synthesis on constrictor responses to phenylephrine. CYP4A1-transfected interlobar arteries demonstrated a twofold increase in CYP4A protein levels and 20-HETE production compared with arteries transfected with the empty plasmid; they also showed increased sensitivity to phenylephrine, as evidenced by a decrease in EC(50) from 0.37 +/- 0.04 microM in plasmid-transfected arteries to 0.07 +/- 0.01 microM in CYP4A1-transfected arteries. The increased sensitivity to phenylephrine was greatly attenuated by N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), a selective inhibitor of 20-HETE synthesis, and by 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid, a specific 20-HETE antagonist. This effect of DDMS was reversed by addition of 20-HETE, further substantiating the notion that increased levels of 20-HETE contribute to the increased sensitivity to phenylephrine in vessels overexpressing CYP4A1. These data suggest that 20-HETE of vascular origin sensitizes renal vascular smooth muscle to phenylephrine.
AbstractList 20-HETE, a cytochrome P-450 4A (CYP4A1)-derived arachidonic acid metabolite, is a major eicosanoid formed in renal and extrarenal microcirculation. 20-HETE inhibits Ca 2+ -activated K + channels in vascular smooth muscle cells and thereby may modulate vascular reactivity. We transfected renal interlobar arteries with an expression plasmid containing the cDNA of CYP4A1, the low- K m arachidonic acid ω-hydroxylase, and examined the consequences of increasing 20-HETE synthesis on constrictor responses to phenylephrine. CYP4A1-transfected interlobar arteries demonstrated a twofold increase in CYP4A protein levels and 20-HETE production compared with arteries transfected with the empty plasmid; they also showed increased sensitivity to phenylephrine, as evidenced by a decrease in EC 50 from 0.37 ± 0.04 μM in plasmid-transfected arteries to 0.07 ± 0.01 μM in CYP4A1-transfected arteries. The increased sensitivity to phenylephrine was greatly attenuated by N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), a selective inhibitor of 20-HETE synthesis, and by 20-hydroxyeicosa-6( Z),15( Z)-dienoic acid, a specific 20-HETE antagonist. This effect of DDMS was reversed by addition of 20-HETE, further substantiating the notion that increased levels of 20-HETE contribute to the increased sensitivity to phenylephrine in vessels overexpressing CYP4A1. These data suggest that 20-HETE of vascular origin sensitizes renal vascular smooth muscle to phenylephrine.
20-HETE, a cytochrome P-450 4A (CYP4A1)-derived arachidonic acid metabolite, is a major eicosanoid formed in renal and extrarenal microcirculation. 20-HETE inhibits Ca(2+)-activated K(+) channels in vascular smooth muscle cells and thereby may modulate vascular reactivity. We transfected renal interlobar arteries with an expression plasmid containing the cDNA of CYP4A1, the low-K(m) arachidonic acid omega-hydroxylase, and examined the consequences of increasing 20-HETE synthesis on constrictor responses to phenylephrine. CYP4A1-transfected interlobar arteries demonstrated a twofold increase in CYP4A protein levels and 20-HETE production compared with arteries transfected with the empty plasmid; they also showed increased sensitivity to phenylephrine, as evidenced by a decrease in EC(50) from 0.37 +/- 0.04 microM in plasmid-transfected arteries to 0.07 +/- 0.01 microM in CYP4A1-transfected arteries. The increased sensitivity to phenylephrine was greatly attenuated by N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), a selective inhibitor of 20-HETE synthesis, and by 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid, a specific 20-HETE antagonist. This effect of DDMS was reversed by addition of 20-HETE, further substantiating the notion that increased levels of 20-HETE contribute to the increased sensitivity to phenylephrine in vessels overexpressing CYP4A1. These data suggest that 20-HETE of vascular origin sensitizes renal vascular smooth muscle to phenylephrine.
Author Kaide, Jun-Ichi
Wang, Ji-Shi
Wang, Mong-Heng
Falck, John R
Nasjletti, Alberto
Laniado-Schwartzman, Michal
Zhang, Fan
Gopal, V Raj
Author_xml – sequence: 1
  givenname: Jun-Ichi
  surname: Kaide
  fullname: Kaide, Jun-Ichi
  organization: Department of Pharmacology, New York Medical College, Valhalla 10595, USA
– sequence: 2
  givenname: Mong-Heng
  surname: Wang
  fullname: Wang, Mong-Heng
– sequence: 3
  givenname: Ji-Shi
  surname: Wang
  fullname: Wang, Ji-Shi
– sequence: 4
  givenname: Fan
  surname: Zhang
  fullname: Zhang, Fan
– sequence: 5
  givenname: V Raj
  surname: Gopal
  fullname: Gopal, V Raj
– sequence: 6
  givenname: John R
  surname: Falck
  fullname: Falck, John R
– sequence: 7
  givenname: Alberto
  surname: Nasjletti
  fullname: Nasjletti, Alberto
– sequence: 8
  givenname: Michal
  surname: Laniado-Schwartzman
  fullname: Laniado-Schwartzman, Michal
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12388396$$D View this record in MEDLINE/PubMed
BookMark eNpFkElPwzAQhS1URBf4BUgoJ24pHjuLc6zKKlXAoSA4WVN3LKVKk2InlfrvcRfEad7ovRl7viHr1U1NjF0DHwOk4g5XG0c1VmPORVKMRShnbBAcEUOSZb2gCwmxSvOvPht6v-KcAwi4YH0QUilZZAP2OXdYe0umLZs6amw0_X5PJhCZ-9dJVNbGEXry0Ra96Sp0UehDdFu2u-BGh_eDaMlVzSLY6IIsyV-yc4uVp6tTHbGPx4f59DmevT29TCez2EhVtLFEIzB8MlNWCWtzEggiTYoC0CqVUA7WmiUos0CeJagEWkzTRSEUQJ5II0fs9rh345qfjnyr16U3VFVYU9N5nYtwZ5bJEJTHoHGN946s3rhyjW6nges9Tv2HUx9w6j3OMHVzWt8t1rT8nznxk7-We3Tx
CitedBy_id crossref_primary_10_1097_CRD_0b013e3182961659
crossref_primary_10_1007_s12403_022_00503_2
crossref_primary_10_1161_HYPERTENSIONAHA_110_154559
crossref_primary_10_1016_j_pharmthera_2018_07_004
crossref_primary_10_1258_ebm_2010_009233
crossref_primary_10_1124_jpet_104_070979
crossref_primary_10_1016_j_prostaglandins_2011_06_006
crossref_primary_10_3390_pharmaceutics9010009
crossref_primary_10_1016_j_cbi_2018_12_004
crossref_primary_10_1161_01_HYP_0000150782_28485_91
crossref_primary_10_1161_HYPERTENSIONAHA_107_089599
crossref_primary_10_1161_01_HYP_0000135658_57547_bb
crossref_primary_10_1161_HYPERTENSIONAHA_111_183301
crossref_primary_10_1111_j_1474_8673_2009_00426_x
crossref_primary_10_1042_CS20120232
crossref_primary_10_1152_ajprenal_00364_2009
crossref_primary_10_1016_j_prostaglandins_2016_05_007
crossref_primary_10_1161_01_RES_0000217283_98806_a6
crossref_primary_10_1016_j_taap_2003_10_010
crossref_primary_10_1111_1556_4029_12664
crossref_primary_10_1097_CRD_0b013e31819d813a
Cites_doi 10.1111/j.1469-7793.1998.771bs.x
10.1172/JCI119279
10.1161/01.HYP.35.1.307
10.1152/ajpheart.1994.266.5.H1879
10.1161/01.HYP.33.1.414
10.1074/jbc.272.43.27345
10.1152/ajpheart.1998.274.1.H27
10.1152/ajpregu.1996.270.1.R217
10.1152/ajpheart.1994.266.5.H2098
10.1152/ajprenal.1999.277.5.F790
10.1152/ajprenal.1999.276.2.F246
10.1152/ajprenal.1994.266.2.F275
10.1152/ajpregu.1998.274.1.R52
10.1152/ajpregu.1996.270.1.R228
10.1038/ki.1997.234
10.1161/01.RES.83.11.1069
10.1073/pnas.95.21.12701
10.1111/j.1476-5381.1992.tb14327.x
10.1161/01.RES.68.4.1154
10.1161/01.RES.72.1.126
10.1161/hy1201.096116
10.1152/ajprenal.00265.2001
10.1042/cs0980277
10.1152/ajpregu.1999.276.6.R1691
10.1152/ajplung.1997.272.5.L823
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1152/ajprenal.00249.2002
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1522-1466
EndPage F56
ExternalDocumentID 10_1152_ajprenal_00249_2002
12388396
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: P01-HL-43400
– fundername: NHLBI NIH HHS
  grantid: R01-HL-18579
– fundername: NIGMS NIH HHS
  grantid: GM-31278
GroupedDBID ---
23M
2WC
39C
4.4
53G
5GY
5VS
6J9
8M5
AAFWJ
ABJNI
ACPRK
ADBBV
AENEX
AFFNX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKKCC
BTFSW
C1A
CGR
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
EMOBN
F5P
GX1
H13
ITBOX
KQ8
NPM
OK1
P2P
PQQKQ
RAP
RHF
RHI
RPL
RPRKH
TR2
W8F
WOQ
XSW
YSK
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c389t-3ac2a93168f82ff7e2a1254991af884e71ffcd18cba064a82afa55b92811743c3
ISSN 1931-857X
IngestDate Fri Oct 25 02:11:00 EDT 2024
Thu Sep 12 17:19:48 EDT 2024
Sat Sep 28 08:40:52 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c389t-3ac2a93168f82ff7e2a1254991af884e71ffcd18cba064a82afa55b92811743c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 12388396
PQID 72883663
PQPubID 23479
ParticipantIDs proquest_miscellaneous_72883663
crossref_primary_10_1152_ajprenal_00249_2002
pubmed_primary_12388396
PublicationCentury 2000
PublicationDate 2003-Jan
2003-01-01
20030101
PublicationDateYYYYMMDD 2003-01-01
PublicationDate_xml – month: 01
  year: 2003
  text: 2003-Jan
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of physiology. Renal physiology
PublicationTitleAlternate Am J Physiol Renal Physiol
PublicationYear 2003
References Laniado-Schwartzman M (B16) 1989; 264
B20
B21
B22
B23
B24
B26
B27
Wang MH (B25) 1998; 284
B28
B29
B10
B11
B12
B13
Carroll MA (B4) 1992; 260
B14
B15
B17
B18
B19
B1
B2
B3
B5
B7
B8
B9
Escalante B (B6) 1988; 248
References_xml – ident: B7
  doi: 10.1111/j.1469-7793.1998.771bs.x
– ident: B21
  doi: 10.1172/JCI119279
– ident: B10
  doi: 10.1161/01.HYP.35.1.307
– ident: B11
  doi: 10.1152/ajpheart.1994.266.5.H1879
– ident: B24
  doi: 10.1161/01.HYP.33.1.414
– ident: B15
  doi: 10.1074/jbc.272.43.27345
– ident: B13
  doi: 10.1152/ajpheart.1998.274.1.H27
– ident: B12
  doi: 10.1152/ajpregu.1996.270.1.R217
– ident: B8
  doi: 10.1152/ajpheart.1994.266.5.H2098
– volume: 264
  start-page: 1165
  year: 1989
  ident: B16
  publication-title: J Biol Chem
  contributor:
    fullname: Laniado-Schwartzman M
– ident: B1
  doi: 10.1152/ajprenal.1999.277.5.F790
– ident: B26
  doi: 10.1152/ajprenal.1999.276.2.F246
– ident: B29
  doi: 10.1152/ajprenal.1994.266.2.F275
– ident: B22
  doi: 10.1152/ajpregu.1998.274.1.R52
– ident: B28
  doi: 10.1152/ajpregu.1996.270.1.R228
– volume: 248
  start-page: 229
  year: 1988
  ident: B6
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Escalante B
– ident: B3
  doi: 10.1038/ki.1997.234
– ident: B23
  doi: 10.1161/01.RES.83.11.1069
– ident: B19
  doi: 10.1073/pnas.95.21.12701
– ident: B9
  doi: 10.1111/j.1476-5381.1992.tb14327.x
– volume: 284
  start-page: 966
  year: 1998
  ident: B25
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Wang MH
– ident: B14
  doi: 10.1161/01.RES.68.4.1154
– ident: B17
  doi: 10.1161/01.RES.72.1.126
– ident: B27
  doi: 10.1161/hy1201.096116
– ident: B18
  doi: 10.1152/ajprenal.00265.2001
– ident: B5
  doi: 10.1042/cs0980277
– volume: 260
  start-page: 104
  year: 1992
  ident: B4
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Carroll MA
– ident: B20
  doi: 10.1152/ajpregu.1999.276.6.R1691
– ident: B2
  doi: 10.1152/ajplung.1997.272.5.L823
SSID ssj0001121
Score 1.9371488
Snippet 20-HETE, a cytochrome P-450 4A (CYP4A1)-derived arachidonic acid metabolite, is a major eicosanoid formed in renal and extrarenal microcirculation. 20-HETE...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage F51
SubjectTerms Amides - pharmacology
Animals
Arachidonic Acid - metabolism
Cytochrome P-450 Enzyme System - genetics
Cytochrome P-450 Enzyme System - metabolism
Cytochrome P450 Family 4
DNA, Complementary
Gene Expression - physiology
Hydroxyeicosatetraenoic Acids - metabolism
Microcirculation - drug effects
Microcirculation - physiology
Phenylephrine - pharmacology
Rats
Rats, Sprague-Dawley
Renal Artery - physiology
Renal Circulation - drug effects
Renal Circulation - physiology
Sulfones - pharmacology
Transfection
Vasoconstrictor Agents - pharmacology
Title Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries
URI https://www.ncbi.nlm.nih.gov/pubmed/12388396
https://search.proquest.com/docview/72883663
Volume 284
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JbxMxFLagSIgLoi1LgBYfEJfggD37MWobhaoNRSQonEYejw1BYlI10wP8ep638VQKYrmMEk9m0Xtfnj8_vwWhlyKKawETH1i_t3qBoiip4lqSOs0yznIKc6zOdz6fpdNFfLpMlsGVbbJL2mokfm7NK_kfrcIY6FVnyf6DZrubwgB8Bv3CETQMx7_TsWGdUnjWd_T5Ih7ToTiejYerRvPBjdwMu2BT-C5cswiTxdKYghs6pBP-1FdDE93pYwp9YVq_odOrMGGcIcYbPwLt6MEw0tlvXXnSZn005J34ugqOe2tcwJZ8IVPp5s3eidMV-Rh-3vmzJw7F3kER9RwU1qYWESV5ki37RpfZxnA30GVN6MQVoJXuW7rd0Ce6cCz_dmmENTKVD03ASZjX_F7-7H05WZydlfOT5fw2usN0SX29e_8hlJUH0klt-IF9U1eeCh7yZssjblKY36xLDD-ZP0D33cICjy1KdtEt2eyh_XHD2_X3H_gVvuh0tIfunruIin30qY8hvFbYYghrDOEOQ9hjCAcMwVls3hkHDGGPoYdoMTmZH02J67VBBFDWlkRcMF7oLmYqZ0plknFqfAeUqzyPZUaVEjXNRcWBxPKcccWTpCqYTlSOIxE9QjvNupFPEI7gclYkoq4jHhe1KmrKqiqtYOXKUhnJAXrtxVde2pIqpVmKJqz00i6NtHWPVDZAL7yISzB9ej-LN3J9vSkz3SkbGPMAPbaSD7cDIgrMP336x2ufoXsBs8_RTnt1LQ-AZrbVoYHIL90zgIw
link.rule.ids 315,786,790,27946,27947
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transfection+of+CYP4A1+cDNA+increases+vascular+reactivity+in+renal+interlobar+arteries&rft.jtitle=American+journal+of+physiology.+Renal+physiology&rft.au=Kaide%2C+Jun-Ichi&rft.au=Wang%2C+Mong-Heng&rft.au=Wang%2C+Ji-Shi&rft.au=Zhang%2C+Fan&rft.date=2003-01-01&rft.issn=1931-857X&rft.volume=284&rft.issue=1&rft.spage=F51&rft.epage=F56&rft_id=info:doi/10.1152%2Fajprenal.00249.2002&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1931-857X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1931-857X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1931-857X&client=summon